リツキシマブ・バイオシミラーの世界市場レポート 2025年

リツキシマブ・バイオシミラー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で51億8,000万米ドルに成長します。予測期間の成長は、高齢化、ヘルスケアアクセスの増加、慢性疾患の有病率の上昇に起因しています。予測期間における主な動向としては、バイオシミラー医薬品の開発に関するFDA規制の改正の活用、新薬開発における研究開発活動を拡大するための大手企業との戦略的パートナーシップや提携契約の締結、効果的かつ革新的なバイオシミラー医薬品の開発のための研究開発活動への広範な投資などが挙げられます。

非ホジキンリンパ腫（NHL）の有病率の増加は、リツキシマブ・バイオシミラー市場の成長を促進すると予想されます。非ホジキンリンパ腫は、身体の免疫システムの重要な構成要素である白血球やリンパ球から発生するがんの一種です。例えば、米国を拠点とするがん擁護団体である米国がん協会は2024年1月、約80,620人（男性44,590人、女性36,030人）が非ホジキンリンパ腫と診断され、基本推定20,140人（男性11,780人、女性8,360人）が死亡すると予測しています。このがんの生涯開発リスクは、男性で約42分の1、女性で52分の1です。したがって、非ホジキンリンパ腫の症例数の増加は、予測期間中にリツキシマブ・バイオシミラーの大きな需要を創出すると予測されます。

自己免疫疾患の有病率の増加は、今後のリツキシマブ・バイオシミラー市場の成長を促進すると予測されています。自己免疫疾患は、身体の免疫システムが健康な組織を異物と誤認して攻撃することで発生します。リツキシマブ・バイオシミラーは、特定のB細胞を標的とすることで、炎症や自己免疫反応を抑制し、これらの疾患の治療に利用されます。例えば、2022年1月、スイスを拠点とする非政府組織である世界経済フォーラムは、自己免疫疾患に対する支出が2021年の1,220億米ドルから2022年には1,400億米ドルに増加したと報告しました。このように、自己免疫疾患の有病率の増加は、リツキシマブ・バイオシミラー市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リツキシマブ・バイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のリツキシマブ・バイオシミラー市場：成長率分析
• 世界のリツキシマブ・バイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のリツキシマブ・バイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界リツキシマブ・バイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリツキシマブ・バイオシミラー市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下
• 静脈内
• 分子タイプ
• 世界のリツキシマブ・バイオシミラー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ホジキンリンパ腫
• 慢性リンパ性白血病
• 関節リウマチ
• その他の用途
• 世界のリツキシマブ・バイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• 通信販売
• 世界のリツキシマブ・バイオシミラー市場、皮下のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレフィルドシリンジ
• 注射ペン
• 世界のリツキシマブ・バイオシミラー市場静脈内注射のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IV輸液ソリューション
• IVプッシュ製剤
• 世界のリツキシマブ・バイオシミラー市場、分子タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 抗体薬物複合体（ADC）

第7章 地域別・国別分析

• 世界のリツキシマブ・バイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリツキシマブ・バイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リツキシマブ・バイオシミラー市場：競合情勢
• リツキシマブ・バイオシミラー市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • BIOCAD Overview, Products and Services, Strategy and Financial Analysis
  • Shanghai Henlius Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Innovent Biologics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sinocelltech
• Cadila Pharmaceuticals
• Hetero Drugs Limited
• Dr. Reddy's Laboratories
• Shanghai Fosun Pharmaceutical（Group）Co. Ltd.
• Reliance Life Sciences India
• Zenotech Laboratories
• NAPP Pharmaceuticals Limited
• Mundipharma Deutschland GmbH & Co. KG
• Celltrion
• Biocad
• MABION S.A.
• Janssen Pharmaceutical
• Amgen
• Teva Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リツキシマブ・バイオシミラー市場2029：新たな機会を提供する国
• リツキシマブ・バイオシミラー市場2029：新たな機会を提供するセグメント
• リツキシマブ・バイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A rituximab biosimilar is a chimeric monoclonal antibody designed to target the B cell-specific protein CD20 within the immune system. This monoclonal antibody, rituximab, is effective in eliminating B cells, making it a valuable treatment for conditions characterized by an excess, overactive, or otherwise abnormal presence of B cells.

Rituximab biosimilars can be administered through various routes, including subcutaneous, intravenous, and molecular methods. Intravenous therapy involves the direct delivery of fluids, medications, and nutrients into a patient's vein. The applications of rituximab biosimilars span across medical conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. These biosimilars are distributed through different channels, including hospital pharmacies, online pharmacies, retail pharmacies, and various direct distribution channels.

The rituximab biosimilars market research report is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market sizes, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rituximab biosimilars market size has grown rapidly in recent years. It will grow from $3.03 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and emerging markets growth.

The rituximab biosimilars market size is expected to see rapid growth in the next few years. It will grow to $5.18 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to aging population, increase in healthcare access, and rising prevalence of chronic diseases. Major trends in the forecast period include leveraging revised FDA regulations for biosimilar drug development, establishing strategic partnerships and collaboration agreements with the large players to expand their research and developments activities in new drug developments, and investing extensively in R&D activities for the development of effective and innovative biosimilars.

The increasing prevalence of non-Hodgkin's lymphoma (NHL) is expected to drive the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma is a type of cancer that originates in white blood cells and lymphocytes, which are essential components of the body's immune system. For example, in January 2024, the American Cancer Society, a US-based cancer advocacy organization, projected that approximately 80,620 individuals (44,590 men and 36,030 women) would be diagnosed with non-Hodgkin lymphoma in 2024, leading to an estimated 20,140 deaths (11,780 men and 8,360 women). The lifetime risk of developing this cancer is about 1 in 42 for men and 1 in 52 for women. Therefore, the rising number of non-Hodgkin's lymphoma cases is anticipated to create significant demand for rituximab biosimilars during the forecast period.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the rituximab biosimilars market in the future. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues, perceiving them as foreign. Rituximab biosimilars are utilized to treat these conditions by targeting specific B cells, thereby reducing inflammation and autoimmune responses. For example, in January 2022, the World Economic Forum, a Switzerland-based non-governmental organization, reported that spending on autoimmune diseases rose from $122 billion in 2021 to $140 billion in 2022. Thus, the growing prevalence of autoimmune diseases is fueling the expansion of the rituximab biosimilars market.

Companies in the biosimilars industry continue to prioritize new product development through collaborations with industry peers. This trend is particularly evident in the rituximab biosimilars market. An example of such collaboration occurred in July 2023 when Dr. Reddy's Laboratories partnered with Fresenius Kabi to commercialize their proposed rituximab biosimilar in the US. The goal of this collaboration is to introduce a more affordable and accessible biosimilar version of rituximab to the market, offering an alternative treatment option for patients. The introduction of a biosimilar rituximab in the United States has the potential to enhance access to this crucial treatment for various conditions, including rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Key players in the rituximab biosimilars market are actively engaged in the development of FDA-approved rituximab biosimilars to establish a competitive advantage. A rituximab biosimilar that receives FDA approval is used in the treatment of specific immune-related conditions and malignancies. For instance, in June 2022, the US-based biopharmaceutical company Amgen Inc. obtained FDA approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab). RIABNI is the only FDA-approved rituximab biosimilar for all available Rituxan indications, encompassing Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), Microscopic Polyangiitis (MPA), and moderately to severely active rheumatoid arthritis (RA) with an inadequate response to TNF antagonist therapies.

Major companies operating in the rituximab biosimilars market include Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Sinocelltech, Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy's Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, NAPP Pharmaceuticals Limited, Mundipharma Deutschland GmbH & Co. KG, Celltrion, Biocad, MABION S.A., Janssen Pharmaceutical, Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

North America was the largest region in the rituximab biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rituximab Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rituximab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rituximab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rituximab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type
• 2) By Application: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications
• 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order
• Subsegments:
• 1) By Subcutaneous: Pre-filled Syringes; Injection Pens
• 2) By Intravenous: IV Infusion Solutions; IV Push Formulations
• 3) By Molecular Type: Monoclonal Antibodies; Antibody-Drug Conjugates (ADCs)
• Companies Mentioned: Novartis AG; Pfizer; BIOCAD; Shanghai Henlius Biotech Inc.; Innovent Biologics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rituximab Biosimilars Market Characteristics

3. Rituximab Biosimilars Market Trends And Strategies

4. Rituximab Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Rituximab Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rituximab Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rituximab Biosimilars Market Growth Rate Analysis
• 5.4. Global Rituximab Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rituximab Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rituximab Biosimilars Total Addressable Market (TAM)

6. Rituximab Biosimilars Market Segmentation

• 6.1. Global Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• Molecular Type
• 6.2. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Hodgkin's Lymphoma
• Chronic Lymphocytic Leukemia
• Rheumatoid Arthritis
• Other Applications
• 6.3. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Mail Order
• 6.4. Global Rituximab Biosimilars Market, Sub-Segmentation Of Subcutaneous, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-filled Syringes
• Injection Pens
• 6.5. Global Rituximab Biosimilars Market, Sub-Segmentation Of Intravenous, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IV Infusion Solutions
• IV Push Formulations
• 6.6. Global Rituximab Biosimilars Market, Sub-Segmentation Of Molecular Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Antibody-Drug Conjugates (ADCs)

7. Rituximab Biosimilars Market Regional And Country Analysis

• 7.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rituximab Biosimilars Market

• 8.1. Asia-Pacific Rituximab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rituximab Biosimilars Market

• 9.1. China Rituximab Biosimilars Market Overview
• 9.2. China Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rituximab Biosimilars Market

• 10.1. India Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rituximab Biosimilars Market

• 11.1. Japan Rituximab Biosimilars Market Overview
• 11.2. Japan Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rituximab Biosimilars Market

• 12.1. Australia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rituximab Biosimilars Market

• 13.1. Indonesia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rituximab Biosimilars Market

• 14.1. South Korea Rituximab Biosimilars Market Overview
• 14.2. South Korea Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rituximab Biosimilars Market

• 15.1. Western Europe Rituximab Biosimilars Market Overview
• 15.2. Western Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rituximab Biosimilars Market

• 16.1. UK Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rituximab Biosimilars Market

• 17.1. Germany Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rituximab Biosimilars Market

• 18.1. France Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rituximab Biosimilars Market

• 19.1. Italy Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rituximab Biosimilars Market

• 20.1. Spain Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rituximab Biosimilars Market

• 21.1. Eastern Europe Rituximab Biosimilars Market Overview
• 21.2. Eastern Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rituximab Biosimilars Market

• 22.1. Russia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rituximab Biosimilars Market

• 23.1. North America Rituximab Biosimilars Market Overview
• 23.2. North America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rituximab Biosimilars Market

• 24.1. USA Rituximab Biosimilars Market Overview
• 24.2. USA Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rituximab Biosimilars Market

• 25.1. Canada Rituximab Biosimilars Market Overview
• 25.2. Canada Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rituximab Biosimilars Market

• 26.1. South America Rituximab Biosimilars Market Overview
• 26.2. South America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rituximab Biosimilars Market

• 27.1. Brazil Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rituximab Biosimilars Market

• 28.1. Middle East Rituximab Biosimilars Market Overview
• 28.2. Middle East Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rituximab Biosimilars Market

• 29.1. Africa Rituximab Biosimilars Market Overview
• 29.2. Africa Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rituximab Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Rituximab Biosimilars Market Competitive Landscape
• 30.2. Rituximab Biosimilars Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. BIOCAD Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Shanghai Henlius Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Innovent Biologics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Rituximab Biosimilars Market Other Major And Innovative Companies

• 31.1. Sinocelltech
• 31.2. Cadila Pharmaceuticals
• 31.3. Hetero Drugs Limited
• 31.4. Dr. Reddy's Laboratories
• 31.5. Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
• 31.6. Reliance Life Sciences India
• 31.7. Zenotech Laboratories
• 31.8. NAPP Pharmaceuticals Limited
• 31.9. Mundipharma Deutschland GmbH & Co. KG
• 31.10. Celltrion
• 31.11. Biocad
• 31.12. MABION S.A.
• 31.13. Janssen Pharmaceutical
• 31.14. Amgen
• 31.15. Teva Pharmaceuticals

32. Global Rituximab Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rituximab Biosimilars Market

34. Recent Developments In The Rituximab Biosimilars Market

35. Rituximab Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Rituximab Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rituximab Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rituximab Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer